Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
H5N1 VLP Vaccine · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Low dose H5N1 VLP Vaccine | EXPERIMENTAL | - |
| Mid dose H5N1 VLP Vaccine | EXPERIMENTAL | - |
| High dose H5N1 VLP Vaccine | EXPERIMENTAL | - |
| Placebo | PLACEBO_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| H5N1 VLP Vaccine | BIOLOGICAL | Two doses - Day 0 \& Day 28 |
| Placebo | BIOLOGICAL | Two doses - Day 0 \& Day 28 |
Inclusion Criteria: 1. Male or female 18 to 40 years of age at the time of the vaccination. 2. Subjects who the investigator believes can and will comply with the requirements of the protocol (e.g., return for follow-up visits and completion of the data collection tool). 3. Available by telephone. ...
H5N1 VLP Vaccine is an investigational vaccine being developed for pandemic influenza. It is designed to protect against H5N1 influenza, a strain that has pandemic potential. The vaccine is currently in clinical development and has not been approved for commercial use.
H5N1 VLP Vaccine is being developed by Novavax, Inc., a biotechnology company traded on the Nasdaq under the ticker symbol NVAX. The company is conducting clinical trials to evaluate the vaccine's safety and immunogenicity for pandemic influenza.
H5N1 VLP Vaccine is in Phase 1 clinical development. It is an investigational vaccine and has not been approved by regulatory authorities. The Phase 1 trial has been completed, and the vaccine remains under investigation for pandemic influenza.
H5N1 VLP Vaccine has one completed clinical trial, identified as NCT00519389, titled 'Safety, Reactogenicity and Immunogenicity of an H5N1 VLP.' This Phase 1 trial enrolled 230 participants in the United States and evaluated the vaccine in healthy volunteers aged 18 years and older.
No, H5N1 VLP Vaccine is not a monoclonal antibody. Although the modality is listed as monoclonal antibody, the vaccine is a virus-like particle (VLP) vaccine designed to elicit an immune response against H5N1 influenza. It is an investigational vaccine, not a therapeutic antibody.